Anticancer chemotherapy often induces side effects such as mucositis. Recent data suggest that a diet, Clinutren Protect (CP), containing whey proteins, glutamine, and transforming growth factor-b (TGFb)-rich casein limits intestinal mucositis and improves recovery after a single methotrexate (MTX) challenge in rats. Chemotherapy consists of alternating periods of treatment and rest. Thus, our study evaluated the effects of CP on nutritional outcome and intestinal mucositis in rats receiving repeated chemotherapeutic challenges. Thirty-six Sprague-Dawley rats received 3 cycles of MTX at 8-d intervals. Rats had free access to CP or control diet (Co) from 7 d before the first MTX injection until the end of the experiment at d 27. In Co, whey proteins and TGFb-rich casein were replaced by TGFb-free casein.
Introduction
Cancer patients are at a high risk for malnutrition due to malignancy-induced cachexia and dysphagia and to the effects of chemoradiation. Chemotherapy, which is often used to treat cancer patients, alternates periods of treatment and rest. The periods of rest between the periods of chemotherapeutic challenge are needed to allow the organism to recover from possible side effects. Among them, mucositis is frequent and is related to many chemotherapeutic agents such as methotrexate (MTX). 7 The onset of mucositis leads to the limitation or even cessation of chemotherapy (1, 2) . The pathophysiology of intestinal mucositis involves hypoproliferation, apoptosis, inflammatory response, and intestinal barrier disruption (3) . We previously reported that MTX treatment also induces an alteration of protein metabolism (4) . Indeed, MTX treatment is associated with a decrease of protein synthesis and an increase of proteolysis and particularly of the lysosomal pathway in jejunal mucosa in rats (5) .
To limit chemotherapy-induced mucositis, nutritional interventions may be beneficial. A new diet, Clinutren Protect (CP), tailored to alleviate intestinal mucositis, has been designed. It contains whey proteins, transforming growth factor-b (TGFb)-rich casein, and free glutamine. These nutrients have been shown to exhibit beneficial effects in various pathological conditions. In colon cancer models in rats, whey protein concentrate had a protective role (6) associated with an increase in the intracellular levels of glutathione (GSH) (7), a major cellular antioxidant (8) . In addition, whey protein is rich in branched-chain amino acids that can stimulate protein synthesis (9) . Glutamine is a conditionally essential amino acid during various conditions of stress (10) . Glutamine is depleted in cancer patients (11) and the content of glutamine is reduced during intestinal inflammation (12) . Glutamine prevents atrophy of the intestinal mucosa in patients receiving total parenteral nutrition (13) and modulates intestinal inflammatory and antioxidant responses (14) . TGFb is an immunomodulatory cytokine that plays an important role in immune function. TGFb can stimulate the IgA production in the intestine (15) , plays a central role in the maintenance of intestinal epithelial homeostasis (16) , and enhances epithelial restitution (17) . We have recently reported that CP reduces intestinal damage in the acute phase of MTX-induced mucositis in rats and improves recovery after a single MTX challenge (18) .
Thus, the aim of the present study was to evaluate the effects of a specific diet containing whey proteins, glutamine, and TGFb on intestinal mucositis and nutritional outcome in rats receiving repeated chemotherapeutic challenges mimicking chemotherapeutic cycles in cancer patients.
Materials and Methods
Rats, housing, diet, and MTX injections. Animal care and experimentation complied with both French and European Community regulations (Official Journal of the European Community L 358, 18/ 12/1986) and M.C. is authorized by the French government to use animal models (authorization no. 76-107). Male Sprague-Dawley rats (350-400 g, Elevage Janvier) were acclimatized at 258C with a 12-h-light/-dark cycle. Rats were individually housed in metabolic cages. Rats were given free access to water and standard diet until d 27, with d 0 being the first day of the first cycle of MTX treatment. From d 27 to d 27, rats received CP or isonitrogenous and isocaloric control (Co) diets. In the Co diet, whey proteins and TGFb-rich casein were replaced by TGFb-free casein. Free L-glutamine was replaced by free L-alanine ( Table 1) . TGFb-free casein contained a standard amount of TGFb (~0.06 mg×g proteins 21 ), whereas TGFb-rich casein contained a high amount of TGFb (~0.29 mg×g proteins 21 ). A chemotherapeutic model was induced by 3 cycles of subcutaneous injections of 2.5 mg×kg 21 MTX (Teva Pharma). The 3 cycles were applied at 8-d intervals between d 0 and 20 (Supplemental Fig. 1 ). Rats were divided into 2 groups: 1) the Co group received MTX injections and had free access to the control diet; and 2) the CP group received MTX injections and had free access to the CP diet. Histology. For histological and immunohistochemistry assessments, jejunal samples were fixed in formalin (10%) and treated as previously described (4, 5) . Briefly, sections were scored by the same pathologist (M. A.) who was unaware of the treatment allocation. Epithelial necrosis, inflammatory cell infiltration, and exocytosis were assessed using semiquantitative scores that ranged from 0 (no damage) to 3 (severe damage) for each marker: villus atrophy, necrosis, inflammation, and exocytosis. Villus height was measured on 10 well-oriented villi from each rodent using the analysis software Leica QWin (Leica Microsystems).
Intestinal GSH concentration. The GSH concentration was assessed in the jejunum by a standardized spectrophotometric assay as previously described (4, 19) . GSH concentration was expressed as mmol×g tissue
IgA content. Frozen fresh feces collected at d 27, 0, 9, 18, and 27 were homogenized with 1 mL extraction buffer (30 mmol×L 21 EDTA, 105 mg×L 21 soybean trypsin inhibitor in PBS). Supernatants were collected after centrifugation at 11,000 3 g for 15 min at 48C and used for analysis of protein content by BCA protein assays and the IgA level, which was measured by ELISA with a commercial kit according to supplier instructions (Bethyl Laboratories) and normalized to the protein content of each fecal extract. (4, 20) . Urine samples were collected over the following 24 h and frozen at 2208C. Iodixanol was assessed in urine by HPLC (20) and the results were expressed as the total amount of iodixanol excreted in urine per day.
Orosomucoid and a2-macroglobulin levels. Orosomucoid and a2-macroglobulin levels were evaluated using a rat orosomucoid ELISA Calculation methods and statistical analysis. Statistical analysis was performed using GraphPad Prism 5.01 (GraphPad Software). For variables evaluated throughout the study in the same rats, statistical analysis consisted of a 2-way ANOVA for repeated measures. Bonferroni post hoc tests were performed when the P-value for interaction was , 0.05. For variables evaluated at one time, a t test was performed when variances were homogeneous as assessed by Bartlett's test. In other cases, a nonparametric Mann-Whitney test was used. Survival curves were compared using the logrank test of Mantel-Cox. For all, P , 0.05 was considered significant. Values in the text are means 6 SE.
Results
At d 27, mortality was~53% and did not differ between the Co and CP groups. Indeed, 7 of 18 rats survived in the Co group (39%) and 10 of 18 rats (55%) in the CP group (Fig. 1) . The following results consider only surviving rats at d 27.
Food intake and body weight. Before the MTX treatment, cumulative food intake was similar in the 2 groups. During each MTX challenge, food intake decreased acutely and then was progressively restored toward a normal level before the next challenge (data not shown). However, the decrease was more pronounced along successive cycles and after the 3rd cycle; the initial level was not restored even on the day before the end of the experiment. All together, cumulative food intake decreased over time in both groups ( Fig. 2A ; P , 0.0001). After the second and 3rd challenges of MTX, cumulative food intake was lower in the Co group than in the CP group (P = 0.02).
During the pretreatment, body weight similarly increased in both groups (Fig. 2B) . After the first chemotherapy cycle, body weight did not increase and remained similar in both groups and then increased until d 10. After the second challenge of MTX, body weight decreased in both groups until d 16 (P , 0.05). The decrease in body weight tended to be greater in the Co group than in the CP group (P , 0.1). Beginning on d 16, body weight increased in both groups. After the 3rd challenge of MTX, body weight sharply decreased in both groups but in a more marked manner in the Co group compared with the CP group. At d 26 (P , 0.05) and d 27 (P , 0.01), body weight was higher in the CP group than in the Co group (Fig. 2B) . Compared with d 0, body weight loss at d 27 was 81.9 6 21.9 g in the Co group and only 34.5 6 15.0 g in the CP group.
Fat mass and fat free mass. Before MTX challenge, body composition was similar in both groups (data not shown). During MTX cycles, fat mass decreased similarly in both groups (Fig. 3A,B) , particularly at d 17. Fat free mass increased similarly in both groups before the second challenge of MTX compared with d 21. After the second MTX cycle (between d 8 and 17), fat free mass decreased similarly in the Co and CP groups. After the 3rd MTX cycle (between d 17 and 27), fat free mass decreased dramatically in the Co group but was unchanged in the CP group (Fig. 3C) . Finally, between d 21 and 27, fat free mass decreased~57.2 6 18.6 g in the Co group and only 9.5 6 11.7 g in the CP group (P , 0.05).
IgA level. For statistical analysis of the fecal IgA level, we were not able to perform 2-way ANOVA for repeated measures because of a lack of fecal samples. For instance, 5 of 17 rats and all rats had no feces at 9 and d 27, respectively. However, when we compared the IgA level between d 27 and 18, it increased in (Fig. 4) .
Orosomucoid and a2-macroglobulin concentrations. The plasma orosomucoid and a2-macroglobulin concentrations increased in both groups between d 21 and 27 (P , 0.001).
The a2-macroglobulin concentration tended to be higher in the Co group than in the CP group (P = 0.08) ( Table 2 ).
Intestinal permeability. Intestinal permeability was not affected by diets and increased similarly in both groups between d 12 (19.9 6 12.2 in Co and 10.2 6 43 in CP, mg urinaryexcreted iodixanol×d 21 ) and d 21 (45.5 6 13.8 in Co and 45.6 6 18.3 in CP).
Intestinal histology and GSH jejunal concentration. At d 27, villus height tended to be higher in the CP group compared with the Co group (P = 0.07) (Fig. 5A) . In addition, the CP group had a lower intestinal damage score than the Co group (P , 0.05) (Fig. 5B) . The jejunal GSH concentration was similar in both groups at d 27 ( Table 2 ).
Discussion
One of the cytotoxic effects of cancer chemotherapy is mucositis, which can affect all parts of the gastrointestinal tract and is characterized by the alteration of absorptive capacity (21) and gut barrier dysfunction (21) . Different mechanisms are involved, such as apoptosis, hypoproliferation, and inflammatory response (22) . In addition, we recently reported that gut protein metabolism is also altered during mucositis (4, 5) . Nutritional approaches could be used to target the mechanisms leading to mucositis and thus may limit intestinal side effects. We previously showed that a treatment with CP induced specific beneficial effects in a model of intestinal mucositis using a single challenge of MTX in rats (18) . In fact, a CP diet limited intestinal damages during the acute phase of mucositis, which was associated with an improvement of intestinal protein metabolism. In addition, CP promoted clinical recovery assessed by an increase of food intake and body weight gain (18) . The beneficial effect of CP may be related to whey proteins, TGFb, and/or glutamine effects on protein metabolism, oxidative stress, or inflammatory response. In cancer patients, chemotherapy alternates periods of treatment and rest. Thus, in the present study, we investigated the effects of CP on nutritional outcome and intestinal mucositis in rats receiving repeated chemotherapeutic challenges.
As expected, we observed in this model of repeated chemotherapeutic cycles that body weight and food intake were more markedly altered compared with 1 cycle of chemotherapy (4, 5) . In addition, the modifications of body composition were different between each cycle. In a previous study (18) , food intake was restored earlier after 1 cycle of MTX in the CP group and consequently body weight recovery was better than in the group receiving the Co diet. In the present work, these beneficial effects of CP were emphasized during repeated MTX cycles. Indeed, in CP-treated rats, the loss of body weight was lower than in the Co rats. This difference could be explained by a better food intake after the MTX challenges in the CP group. These data may suggest a better intestinal tolerance to feeding in rats receiving the CP diet compared with those receiving the Co diet. The faster absorption of whey protein compared with casein (23) and a potential effect of CP on central regulation of food intake may also be implicated. In addition, in the present study, we evaluated the changes of body composition. Fat mass decreased in both groups during the 2 first challenges of MTX, whereas fat free mass decreased only after the second challenge. After the 3rd challenge, fat free mass was affected in only the Co group. In contrast, in the CP group, fat free mass was preserved. In cancer patients, it is well known that sarcopenia is associated with lower survival (24) and higher chemotherapy toxicity (25) . Interestingly, in our study, when we compared fat free mass changes between surviving and dead rats, surviving rats had a lower reduction of fat free mass compared with dead rats regardless of the nutritional treatment (P , 0.01; Fig. 6 ). The preservation of fat free mass also has a good predictive value for outcomes in our model. Thus, the preserved fat free mass in rats receiving CP may be beneficial for the recovery after chemotherapy. This effect may be due to whey proteins, which contain branched-chain amino acids and thus can stimulate protein synthesis (9, 26, 27) and limit muscle protein catabolism (28) . Whey protein ingestion was also associated with an increase of fat free mass in healthy rats (29) . We previously reported that a CP diet restored protein metabolism in intestinal mucosa in MTX-treated rats (18) , but its effects on muscle protein metabolism during mucositis remain unknown.
As expected, plasma orosomucoid and a2-macroglobulin levels increased over time, suggesting that a systemic inflammatory response appeared after the second chemotherapeutic challenge. We did not observe a significant difference between the Co and CP groups. However, a trend for a lower inflammatory response was observed in rats receiving the CP diet (P = jn.nutrition.org 0.08) that could be a consequence of an improved intestinal barrier function. Intestinal permeability, which was evaluated by iodixanol urinary excretion as previously described (4), increased similarly over time in both groups. GSH plays a key role in the antioxidant system. In the present study, the GSH jejunal concentration was similar in the CP and Co groups. In our previous study, the GSH concentration increased during the acute phase of mucositis after a single MTX challenge in rats receiving CP but not during recovery phase (18) . In the present study, the GSH concentration was assessed at only the recovery phase. Thus, a potential benefit may have occurred earlier along each chemotherapy cycle and may have disappeared 1 wk after the last MTX treatment. We also evaluated the fecal IgA level. Secretory IgA plays a major role in the intestinal barrier function by surveillance of commensal bacteria and exclusion of pathogens. In addition, secretory IgA enhances innate immune defenses in the intestinal epithelium (30) . In the CP group, the IgA level increased over time, whereas it remained unchanged in the Co group. This difference may contribute to enhance intestinal defenses against pathogens and to limit infections. Unfortunately, we were not able to analyze IgA at d 27 because of a lack of feces. Thus, the benefit observed for the IgA level change was obtained between d 7 and 18. An extrapolation of the benefits observed on other parameters such as body weight change, body composition, and inflammation, which increased from one cycle to the following one, suggests that the difference in the IgA level between the 2 groups could be higher at d 27 and contributes to the overall protective effect on the intestinal mucosa. Whey protein may be responsible for this increase of IgA because it contains Ig (31), but the CP diet also contained TGFb, which plays a pivotal role in the stimulation of IgA at mucosal sites (32) . Indeed, Borsutzky et al. showed that IgA production in intestinal mucosa was lower in knockout mice for the receptor of TGFb (32) . Glutamine may also enhance IgA production as previously reported in parenterally fed rats (33) . Further studies are needed to evaluate which nutrient contributed to the CP effects on the fecal IgA level.
We also observed that intestinal damage was lower in the CP group than in the Co group. Indeed, we observed a trend for higher villus height but especially a strong decrease of damage score in the CP group. We were not able to determine which nutrient is responsible for these effects, but previous studies reported beneficial effects of each active nutrient included in the CP diet. Indeed, whey proteins reduced MTX-induced damage in the small bowel (34) and improved gut permeability (35) . Similarly, it was reported that TGFb reduced the severity of oral mucositis after 5-fluorouracil treatment in hamsters (36) . Finally, several studies showed that glutamine improved intestinal damage during chemotherapy-induced mucositis (37) (38) (39) (40) . However, the present study is the first to our knowledge to show that an integrated diet can improve intestinal damage after successive cycles of chemotherapeutic treatment and rest.
In conclusion, a specific diet containing whey proteins, glutamine, and TGFb has protective effects in rats receiving repeated chemotherapeutic cycles by improving nutritional outcome and decreasing intestinal damage. Although we were not able to determine in the present study which nutrients are responsible for these effects, these observations should be consolidated in a tumor-bearing model and more importantly in a clinical study in cancer patients.
